Comparison Overview

Inspire Pharma

VS

AbbVie

Inspire Pharma

4 El Tahrir St, Sheraton Heliopolis sheraton heliopolis Cairo, EG
Last Update: 2025-03-14 (UTC)
View Profile
Between 800 and 849
http://www.inspirepharma.com

Inspire pharma is a national Egyptian pharmaceutical company established in 2005, founded by a determined group of partners to be a unique business model in the healthcare industry in Egypt. After a three-year ride in legislative and licensing processes, we were successful in acquiring distinguished talents at several levels to drive and deliver organizational KPIs. Together with 100 molecules cued up in the pipeline 15 molecules were launched successfully since 2010 . Our management team is not only emphasizing the financial objectives, but rather, it’s equally determined to establish a unique business culture and inspiring code of conduct through our core values.

NAICS: 325
NAICS Definition:
Employees: 201-500
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

AbbVie

1 Waukegan Road, None, North Chicago, Illinois, US, 60064
Last Update: 2025-09-15 (UTC)
Between 800 and 849
http://www.abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 58,020
Subsidiaries: 15
12-month incidents
0
Known data breaches
1
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/inspire-pharma.jpeg
Inspire Pharma
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/abbvie.jpeg
AbbVie
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Inspire Pharma
100%
Compliance Rate
0/4 Standards Verified
AbbVie
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Inspire Pharma in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AbbVie in 2025.

Incident History — Inspire Pharma (X = Date, Y = Severity)

Inspire Pharma cyber incidents detection timeline including parent company and subsidiaries

Incident History — AbbVie (X = Date, Y = Severity)

AbbVie cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/inspire-pharma.jpeg
Inspire Pharma
Incidents

No Incident

https://images.rankiteo.com/companyimages/abbvie.jpeg
AbbVie
Incidents

Date Detected: 06/2023
Type:Breach
Attack Vector: Exploitation of Vulnerability
Motivation: Financial gain
Blog: Blog

FAQ

Inspire Pharma company demonstrates a stronger AI Cybersecurity Score compared to AbbVie company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

AbbVie company has historically faced a number of disclosed cyber incidents, whereas Inspire Pharma company has not reported any.

In the current year, AbbVie company and Inspire Pharma company have not reported any cyber incidents.

Neither AbbVie company nor Inspire Pharma company has reported experiencing a ransomware attack publicly.

AbbVie company has disclosed at least one data breach, while Inspire Pharma company has not reported such incidents publicly.

Neither AbbVie company nor Inspire Pharma company has reported experiencing targeted cyberattacks publicly.

Neither Inspire Pharma company nor AbbVie company has reported experiencing or disclosing vulnerabilities publicly.

Neither Inspire Pharma nor AbbVie holds any compliance certifications.

Neither company holds any compliance certifications.

AbbVie company has more subsidiaries worldwide compared to Inspire Pharma company.

AbbVie company employs more people globally than Inspire Pharma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Inspire Pharma nor AbbVie holds SOC 2 Type 1 certification.

Neither Inspire Pharma nor AbbVie holds SOC 2 Type 2 certification.

Neither Inspire Pharma nor AbbVie holds ISO 27001 certification.

Neither Inspire Pharma nor AbbVie holds PCI DSS certification.

Neither Inspire Pharma nor AbbVie holds HIPAA certification.

Neither Inspire Pharma nor AbbVie holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References